Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use

CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.